Avita Medical-Nachfolgethread-AvitaTherapeutics

Zitat:"...For the fiscal quarter ending June 30, 2021, AVITA Medical has to date realized total revenue in excess of its fiscal fourth quarter guidance range of $8.2 million to $8.6 million. Based on the strength of both RECELL® commercial revenue and BARDA related revenue, the Company is raising fiscal Q4 guidance to be in the range of $9.5 - $9.7 million, consisting of $6.0 - $6.2 million of RECELL® commercial revenue and $3.5 million of RECELL® revenue associated with BARDA, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority within the Office of the Assistance Secretary for Preparedness and Response. RECELL® commercial revenue as revised in the guidance reflects a 55% to 60% increase over the prior year period and 30% to 34% increase over the third quarter of 2021. ..." ENDE Zitat
Quelle:https://www.stockwatch.com/News/Item/U-z8255089-U!RCEL-20210615/U/RCEL  

Zitat:"..AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results....VALENCIA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. ....... today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021............Fourth Quarter of Fiscal Year 2021 Highlights................    Total net revenue increased 166% to $10.3 million compared to $3.9 million in the fourth quarter of 2020...................    Total commercial revenue increased 45% to $6.7 million compared to the prior quarter ended March 31, 2021 and exceeded revised revenue guidance of $6.0-6.2 million.............................Gross profit margin of 80% compared to 77% in the fourth quarter of 2020..............    Net loss of $4.7 million, or $0.19 per share compared to a net loss of $12.9 million, or $0.60 per share in the fourth quarter of 2020........................... As of June 30, 2021, the Company had $110.7 million in cash and cash equivalents, and no debt
   FDA approved expanded use of the RECELL® System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients.............Full-Year of Fiscal 2021 Highlights...............    Total net revenue increased 105% to $29.2 million compared to $14.3 million in the prior year......................    Commercial revenues increased 50% compared to the prior year.......    Gross profit margin of 80% compared to 79% in the prior year
   Net loss of $26.6 million, or $1.17 per share compared to a net loss of $42.0 million, or $2.07 per share, in the prior year........" ENDE Zitat
Quelle:https://www.stockwatch.com/News/Item/U-z8315923-U!RCEL-20210826/U/RCEL  

Zitat:" financial results for its first fiscal quarter ended September 30, 2021.
First Quarter Fiscal Year 2022 Highlights.....    Total revenue increased 39% to $7.0 million compared to $5.1 million in the first fiscal quarter of 2021....    Gross profit margin improved 3% to 85% compared to the first fiscal quarter of 2021....    Total operating expenses decreased 18% to $12.3 million compared to $14.9 million in the first fiscal quarter of 2021....    Net loss of $5.9 million, or $0.24 per share compared to a net loss of $10.2 million, or $0.48 per share in the first fiscal quarter of 2021....    As of September 30, 2021, the Company had $60.4 million in cash and cash equivalents and $49.5 million in short-term and long-term marketable securities, and no debt....."Ende Zitat
Source:https://www.stockwatch.com/News/Item/U-z8388525-U!RCEL-20211108/U/RCEL

Links:
https://ir.avitamedical.com/
https://www.barchart.com/stocks/quotes/RCEL/interactive-chart
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=RCEL (buy)
https://www2.asx.com.au/markets/company/AVH
https://sec.report/Document/0001193125-21-326416/d249729dex992.htm